Navigation Links


Cystinosis in Medical News

Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference

... development of the product candidate, at the cystinosis Research Network ("CRN") Family Conference, taking place July 16-18, 2009 in Atlanta, GA. cystinosis is a rare genetic disease characterized by the ... in the first two years of life. Failure to treat cystinosis can cause serious health consequences, including ...

2009 Science Report on Genetic Disease Released by Cystinosis Research Foundation

... Researchers of the genetic disease cystinosis report encouraging news. The cystinosis Research Foundation has published the third ... Report, which is designed to provide updates on cystinosis research under way and includes new abstracts of ...

Cystinosis Research Network Unveils New Communication Strategy and Website

... cystinosis Research Network, a non-profit organization ... Lake Forest, IL (PRWEB) January 29, 2009 -- The cystinosis Research Network, a non-profit organization aimed ... the organization's efficacy as the voice of the cystinosis community. President and Executive Director ...

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement

... populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis , non-alcoholic steatohepatitis ("NASH") , Huntington's Disease ("HD") , and aldehyde dehydrogenase ("ALDH2") deficiency . Raptor's ...
Cystinosis in Medical Technology

Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease

... Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare, genetic lysosomal storage ... to initiate a pivotal study of DR Cysteamine in cystinosis patients in 2009. About Raptor Pharmaceuticals ... ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). ...

Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

... Cysteamine ("DR Cysteamine") for the potential treatment of nephropathic cystinosis ("cystinosis"), non-alcoholic steatohepatitis ("NASH") and Huntington's ... Company expects to conduct its pivotal clinical study for DR Cysteamine in cystinosis in the second half of 2009 and file an NDA in 2010. In February, ...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

... ("FDA") and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), has demonstrated potential efficacy in preclinical and ... is to leverage cysteamine's known safety profile for the treatment of cystinosis and potential efficacy in several other indications. In this case, ...

Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)

... ("FDA") and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare and genetic lysosomal storage disease. Raptor is ... Raptor's ability to develop DR Cysteamine for the treatment of NASH, cystinosis and other indications; Raptor's ability to formulate and manufacture DR ...

Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program

... the greatest potential impact. Raptor is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting ...

Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease

... involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from ...
Cystinosis in Medical Definition

Pathology

... , Propionic acidemia , Methylmalonic acidemia , Isovaleric acidemia , 3-Methylcrotonyl-CoA carboxylase deficiency ) - Transport ( Cystinuria , cystinosis , Hartnup disease ) - Sulfur ( Homocystinuria , Cystathioninuria ) - Urea cycle ( Argininosuccinic aciduria , Citrullinemia , ...
Cystinosis in Medical Dictionary

Cystinosis

... cystinosis follows a pattern of autosomal recessive ... they also have a normal gene to compensate. cystinosis - an inherited disorder whereby the kidney s ... which binds excess copper in the blood . cystinosis is treated with cysteamine, which removes ...

Fructose

... RTA can also result from inherited disorders that disrupt the body's normal breakdown and use of nutrients. Examples include the rare disease cystinosis (in which cystine crystals are deposited in bones and other tissue s), hereditary fructose ... Read the ingredient list for packaged foods ...

Metabolism

... less than 1% of the T3 is free. Cystine is made by cells during metabolism . Normally the amino acid is carried out of the cell but in cystinosis the cystine cannot be transported out. Thyroid cancer : Cancer of the gland in front of the neck that normally produces thyroid hormone ...
Cystinosis in Biological News

Brain-nourishing molecule may predict schizophrenia relapse

... Exercise can increase BDNF levels. Two drugs currently on the market for other medical conditions erythropoietin for anemia and cysteamine for cystinosis can as well. Dr. Pillai hopes his laboratory studies of these drugs will soon result in an adjunct therapy that can help patients avoid devastating ...
Cystinosis in Biological Technology

Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis

... ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage ... The Phase 2b clinical trial will enroll up to six cystinosis patients with a history of good compliance using ... study with a pivotal, Phase 3 clinical study in cystinosis patients anticipated to commence in the fourth ...

Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008

... cystinosis Foundation Ireland to Host Event June 27-28, ... Raptor's clinical division, will present at the cystinosis Foundation Ireland's 5th International cystinosis Conference to be held June 27-28, 2008 at ...

Raptor Pharmaceuticals Acquires Orphan Clinical Program

... in a clinical trial generously supported by the cystinosis Research Foundation of Irvine, CA. The active ... the lead clinical investigator for the ongoing cystinosis trial. "Although cysteamine bitartrate has been ... "Through the generous and untiring support of the cystinosis Research Foundation over the past five years, we ...

Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)

... FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. ... deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division ...

Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline

... is currently approved by the FDA for the management of nephropathic cystinosis ("cystinosis"), a genetic lysosomal storage disease characterized by the ... rights to Cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases. In addition to our ongoing clinical trial ...

Raptor Pharmaceuticals Closes $10 Million Private Placement

... approval and commercialization. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. ...

Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention

... currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and NASH. For additional information, please visit http://www.raptorpharma.com . FORWARD LOOKING STATEMENTS This document contains ...

Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease

... currently approved indications. Bennu's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and NASH. For additional information, please visit http://www.raptorpharma.com . FORWARD LOOKING STATEMENTS This ...
Other Contentsbasophilsbasophilsbicepsbicepsbellybellybellybellybicuspidbilateralbilateralbilateralbilateralbilebilebilebilebilefissionfissionbinarybinarybinarybinary
(Date:12/17/2009)... Climate Conference in Copenhagen approaches its conclusion, negotiations ... mitigating climate change. The new ,Reducing Emissions from ... support as a central element of any new ... of global greenhouse gas emissions, this new policy ... contribution to emissions reduction. Linked to this, developed ...
(Date:12/17/2009)... Campaign Invites Personal Stories of Inspiration on How Exercise Has Helped, ... ... December 17, 2009 -- The International Health, Racquet & Sportsclub Association ... Healthier America, it is urging Americans of all ages and abilities ... to create a culture of movement in America wherein regular daily ...
(Date:12/17/2009)... screening within year of first intercourse , , THURSDAY, Dec. ... U.S. cities, about half acquire at least one of ... trichomoniasis -- within two years of becoming sexually active, ... 381 girls, aged 14 to 17, also found that ... infections. , "Depending on the organism, within four to ...
(Date:12/17/2009)... Master of Science in Human Resource Development Degree Online ... ... 2009 -- Open enrollment has begun for Villanova’s newly online ... working professionals whose busy schedules can’t accommodate a campus-based program. ... debuting online in March 2010, location is no longer a ...
(Date:12/17/2009)... DIEGO, Dec. 17 Neurocrine Biosciences, Inc. (Nasdaq: ... into a privately negotiated transaction to sell an aggregate ... affiliates of Venrock at a price of $2.09 per ... $10 million. Neurocrine expects the financing to close on ... conditions. ,, A shelf registration statement relating ...
Breaking Medicine News(10 mins):Health News:Forests take center stage at Copenhagen 2Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5Health News:STDs Common Among Sexually Active Teen Girls in Cities 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3
(Date:12/16/2009)... (Climate-KIC)" is a major initiative the EIT has announced ... expertise of world class partners in a shared effort ... meet the climate change challenge in the years to ... In responding to this challenge, we need to bring ... goods, and to how we meet our requirements for ...
(Date:12/16/2009)... drop of water is a high priority for grape growers in ... vines have to be irrigated to make it through the growing ... the water applied to the vines zips right by the plants, ... of the water that is applied is lost below the vine ... vine roots," said Eve Hinckley, who worked on the project for ...
(Date:12/16/2009)... can help them get psyched up for contests, but ... many athletes gobble down before and during events, they ... agents are treatments for the symptoms of an injury, ... at Indiana University focuses on musculoskeletal health and sports ... train at a certain level, but pain occurs for ...
Breaking Biology News(10 mins):Innovation boost to tackle climate change 2Innovation boost to tackle climate change 3Lost water of the Napa Valley vineyards 2Lost water of the Napa Valley vineyards 3Lost water of the Napa Valley vineyards 4NSAIDs: Take 'em early and often when competing? Think again 2U of As David Schindler confirms untold levels of oil sands pollution on the Athabasca 11020 1 242 4 million stimulus fuels effort to regenerate injured spinal cords 11018 1 242 4 million stimulus fuels effort to regenerate injured spinal cords 11018 2 242 4 million stimulus fuels effort to regenerate injured spinal cords 11018 3 242 4 million stimulus fuels effort to regenerate injured spinal cords 11018 4Docs Not Giving Clear Advice on Infant Sleep Positions 62777 1Docs Not Giving Clear Advice on Infant Sleep Positions 62777 2Docs Not Giving Clear Advice on Infant Sleep Positions 62777 3
Other TagsHYBHYBHYBHYBHYBAntibodyShopCorpCorpCorpCorpUSBUSBearsearsearsearsearsbenditchitchitchitchitchmainmainmainmainmainOther Tagsenhance 2enhance 3enhance 4enhance 5enhance 6enhance 7enhance 8enhance 9enhance 10lawsuit 2lawsuit 3chemically 2chemically 3chemically 4chemically 5preventing 2preventing 3preventing 4preventing 5preventing 6preventing 7preventing 8preventing 9preventing 10